Ipsen S.A. operates as a biopharmaceutical company worldwide. More Details
Good value with adequate balance sheet and pays a dividend.
Share Price & News
How has Ipsen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IPN is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: IPN's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: IPN exceeded the French Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: IPN underperformed the French Market which returned 48.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Ipsen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIpsen S.A.'s (EPA:IPN) Stock Is Going Strong: Have Financials A Role To Play?
4 weeks ago | Simply Wall StEarnings Beat: Ipsen S.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
1 month ago | Simply Wall StAn Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 49% Undervalued
Is Ipsen undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IPN (€82.62) is trading below our estimate of fair value (€143.89)
Significantly Below Fair Value: IPN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IPN is good value based on its PE Ratio (12.6x) compared to the French Pharmaceuticals industry average (16.2x).
PE vs Market: IPN is good value based on its PE Ratio (12.6x) compared to the French market (24.6x).
Price to Earnings Growth Ratio
PEG Ratio: IPN's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: IPN's PB Ratio (3.2x) is in line with the FR Pharmaceuticals industry average.
How is Ipsen forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IPN's earnings are forecast to decline over the next 3 years (-1.3% per year).
Earnings vs Market: IPN's earnings are forecast to decline over the next 3 years (-1.3% per year).
High Growth Earnings: IPN's earnings are forecast to decline over the next 3 years.
Revenue vs Market: IPN's revenue (1.6% per year) is forecast to grow slower than the French market (6.8% per year).
High Growth Revenue: IPN's revenue (1.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IPN's Return on Equity is forecast to be low in 3 years time (18%).
How has Ipsen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IPN has a large one-off loss of €208.6M impacting its December 31 2020 financial results.
Growing Profit Margin: IPN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: IPN's earnings have declined by 1.6% per year over the past 5 years.
Accelerating Growth: IPN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IPN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.9%).
Return on Equity
High ROE: IPN's Return on Equity (25.7%) is considered high.
How is Ipsen's financial position?
Financial Position Analysis
Short Term Liabilities: IPN's short term assets (€1.6B) exceed its short term liabilities (€1.2B).
Long Term Liabilities: IPN's short term assets (€1.6B) exceed its long term liabilities (€982.3M).
Debt to Equity History and Analysis
Debt Level: IPN's debt to equity ratio (49.1%) is considered high.
Reducing Debt: IPN's debt to equity ratio has increased from 3.8% to 49.1% over the past 5 years.
Debt Coverage: IPN's debt is well covered by operating cash flow (74%).
Interest Coverage: IPN's interest payments on its debt are well covered by EBIT (29.7x coverage).
What is Ipsen current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: IPN's dividend (1.21%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.33%).
High Dividend: IPN's dividend (1.21%) is low compared to the top 25% of dividend payers in the French market (3.94%).
Stability and Growth of Payments
Stable Dividend: IPN's dividends per share have been stable in the past 10 years.
Growing Dividend: IPN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (15.2%), IPN's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: IPN's dividends in 3 years are forecast to be thoroughly covered by earnings (13.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Loew (53 yo)
Mr. David Loew has been the Chief Executive Officer and Director of Ipsen S.A. since July 1, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at Sanofi since July 6, 2017 until June 1...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD5.84M) is above average for companies of similar size in the French market ($USD2.96M).
Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.
Experienced Management: IPN's management team is considered experienced (3.7 years average tenure).
Experienced Board: IPN's board of directors are considered experienced (9.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ipsen S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Ipsen S.A.
- Ticker: IPN
- Exchange: ENXTPA
- Founded: 1929
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €6.824b
- Shares outstanding: 82.60m
- Website: https://www.ipsen.com
Number of Employees
- Ipsen S.A.
- 65, quai Georges Gorse
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuli...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 19:37|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.